Toronto, Canada; Rehovot, Israel; Bangkok, Thailand (PRWEB) July 24, 2006
Leading stem cell research journal ‘Regenerative Medicine’ recently confirmed the achievements of TheraVitae Ltd. by naming the Israeli-Thai company as being a ‘serious player in the international arena of regenerative therapy’. The bi-monthly journal, which provides a forum to address advances in stem cell research and regenerative medicine, makes the pronouncement in an article in the July 2006 issue.
Backed by the opinions of an International Editorial Board of over 65 experts, the periodical’s July round-up of industry news goes on to conclude that VesCell™, TheraVitae’s treatment for heart disease, provides the best commercially available stem cell-based treatment for ‘no-option’ cardiac patients. These are patients afflicted by severe medical conditions that cannot be treated using conventional procedures such as bypass surgery or balloon angioplasty due to the risks associated with these options.
Patients are treated with self-derived stem cells isolated by TheraVitae’s proprietary technology. Angiogenic cell precursors harvested from the patients’ peripheral blood in Bangkok are expanded and differentiated in-vitro in a facility in Israel. The product, VesCell™, is sent back to Thailand where is injected, either directly into patient’s heart, or delivered via intracoronary catheter.
Stressing that TheraVitae’s aim is not to seek a miracle cure for heart disease but to provide sufferers a new lease on life and the chance to once again enjoy activities which they never thought possible, Dr Valentin Fulga, CEO of TheraVitae is quoted, in Regenerative Medicine’s July 2006 issue, as saying, “Depending on the disease, we follow improvement in perfusion of the ischemic region in the heart in patients with angina pectoris, or ejection fraction for patients with heart failure. However, our cardinal assessment parameters remain the general condition of the patient and improvement in his/her ability to perform regular daily tasks”.
About Future Medicine & Regenerative Medicine Journal
The Future medicine series delivers essential information in concise, at-a-glance article formats for increasingly time-constrained clinicians and research professionals. Key scientific and clinical issues are reported and analyzed by international experts, providing authoritative but accessible forums for a new era of healthcare.
Regenerative Medicine (ISSN: 1746-0751) provides a forum to address the important challenges and advances in stem cell research and regenerative medicine. It includes Review articles, Original Research, Editorials, Technology Evaluations, Interviews, Perspectives and more, all subject to rigorous peer review, supported by the International Editorial Board of over 65 experts.
Future Medicine: http://www.futuremedicine.com
Regenerative Medicine Magazine: http://www.futuremedicine.com/loi/rme
About VesCell™ - A Natural Treatment for Heart Disease
The body has natural ways of healing itself and the cardiovascular system is no exception. Angiogenic Cell Precursors (ACPs) originate in bone marrow and then circulate in the blood vessels. To manufacture VesCell, TheraVitae expands a small number of ACPs harvested from about 250cc of blood into a therapeutic quantity. VesCell is injected either through a coronary artery via catheter, or during surgery, directly into the heart muscle.
A key aspect of VesCell therapy is the advanced cell isolation and expansion technique that allows for the ACPs to be harvested from blood collected in a procedure similar to a common blood donation. VesCell uses a patient's own adult stem cells to treat Heart Disease and is a viable therapeutic possibility for heart patients without any other treatment option.
Additional Information on Stem Cell Therapy:
VesCell Website: http://www.vescell.com
Stem Cell Therapy Blog: http://stem-cell-therapy.blogspot.com
TheraVitae is a private, multinational company focused on using stem cells from the patient's own blood in order to treat a variety of disorders, especially cardiovascular diseases. The company has already developed a proprietary stem cell technology ‘VesCell™’ that is currently being used by hospitals in Thailand to treat patients with Heart Disease. TheraVitae is based in Bangkok, Thailand, Kiryat Weizmann, Israel, Toronto, Canada, Singapore, Taipei, Taiwan and Hong Kong.
36/72 PS Tower, 21/Fl., Sukhumvit 21, Klongtoey Nua, Bangkok 10110
7 Pinhas Sapir Street P.O. Box 4049, Ness Ziona 74140, Israel
# # #